These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 16648883)
1. Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? Forbes JM; Soldatos G; Thomas MC Clin Biochem Rev; 2005 Nov; 26(4):123-34. PubMed ID: 16648883 [TBL] [Abstract][Full Text] [Related]
2. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. Neviere R; Yu Y; Wang L; Tessier F; Boulanger E Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623 [TBL] [Abstract][Full Text] [Related]
3. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. Teissier T; Boulanger É Biogerontology; 2019 Jun; 20(3):279-301. PubMed ID: 30968282 [TBL] [Abstract][Full Text] [Related]
4. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300 [TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. Kumar Pasupulati A; Chitra PS; Reddy GB Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946 [TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Deluyker D; Evens L; Bito V Amino Acids; 2017 Sep; 49(9):1535-1541. PubMed ID: 28710551 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation. Sourris KC; Watson A; Jandeleit-Dahm K Handb Exp Pharmacol; 2021; 264():395-423. PubMed ID: 32809100 [TBL] [Abstract][Full Text] [Related]
8. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention. Yamagishi S; Matsui T Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289 [TBL] [Abstract][Full Text] [Related]
9. Assay for advanced glycation end products generating intracellular oxidative stress through binding to its receptor. Kobori T; Ganesh D; Kumano-Kuramochi M; Torigoe K; Machida S Anal Biochem; 2020 Dec; 611():114018. PubMed ID: 33186591 [TBL] [Abstract][Full Text] [Related]
10. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Yamagishi S Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404 [TBL] [Abstract][Full Text] [Related]
11. Fructose causes endothelial cell damage via activation of advanced glycation end products-receptor system. Sotokawauchi A; Matsui T; Higashimoto Y; Yamagishi SI Diab Vasc Dis Res; 2019 Nov; 16(6):556-561. PubMed ID: 31375034 [TBL] [Abstract][Full Text] [Related]
12. Receptor for advanced glycation end products modulates oxidative stress and mitochondrial function in the soleus muscle of mice fed a high-fat diet. Velayoudom-Cephise FL; Cano-Sanchez M; Bercion S; Tessier F; Yu Y; Boulanger E; Neviere R Appl Physiol Nutr Metab; 2020 Oct; 45(10):1107-1117. PubMed ID: 32289236 [TBL] [Abstract][Full Text] [Related]
13. AGE, RAGE, and ROS in diabetic nephropathy. Tan AL; Forbes JM; Cooper ME Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682 [TBL] [Abstract][Full Text] [Related]
15. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684 [TBL] [Abstract][Full Text] [Related]
16. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603 [TBL] [Abstract][Full Text] [Related]
17. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Sourris KC; Forbes JM Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535 [TBL] [Abstract][Full Text] [Related]
18. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Fishman SL; Sonmez H; Basman C; Singh V; Poretsky L Mol Med; 2018 Nov; 24(1):59. PubMed ID: 30470170 [TBL] [Abstract][Full Text] [Related]
19. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646 [TBL] [Abstract][Full Text] [Related]
20. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure. Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]